Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Azenta, Inc. - Common Stock (NQ:AZTA)

26.77 -0.94 (-3.39%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Azenta, Inc. - Common Stock

< Previous 1 2 3 4 Next >
AZTA Q1 Earnings Call: Revenue Tops Expectations, Margin Progress Amid Macro Headwinds
Life sciences company Azenta (NASDAQ:AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.05 per... 
Via StockStory
Topics World Trade
Exposures Tariff
Azenta (NASDAQ:AZTA) Beats Q1 Sales Targets
Life sciences company Azenta (NASDAQ:AZTA) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 5.2% year on year to $143.4 million. Its non-GAAP profit of $0.07 per... 
Via StockStory
Earnings Scheduled For May 7, 2025
Via Benzinga
Insights Ahead: Azenta's Quarterly Earnings
Via Benzinga
Azenta (AZTA) Q1 Earnings Report Preview: What To Look For
Life sciences company Azenta (NASDAQ:AZTA) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
A Glimpse Into The Expert Outlook On Azenta Through 4 Analysts
Via Benzinga
Earnings Scheduled For February 5, 2025
Via Benzinga
2 Cash-Heavy Stocks Worth Your Attention and 1 to Approach with Caution
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
3 Cash-Producing Stocks Facing Headwinds
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
3 Reasons AZTA is Risky and 1 Stock to Buy Instead
Shareholders of Azenta would probably like to forget the past six months even happened. The stock dropped 23.7% and now trades at $37.66. This might have investors contemplating their next move. 
Via StockStory
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how IQVIA (NYSE:IQV) and the rest... 
Via StockStory
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at West Pharmaceutical Services (NYSE:WST) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
Unpacking Q4 Earnings: UFP Technologies (NASDAQ:UFPT) In The Context Of Other Drug Development Inputs & Services Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at drug development inputs & services stocks,... 
Via StockStory
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Azenta (NASDAQ:AZTA) and its peers. 
Via StockStory
1 Small-Cap Stock with Exciting Potential and 2 to Brush Off
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
What To Expect From Fortrea’s (FTRE) Q4 Earnings
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know. 
Via StockStory
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
Medical products company UFP Technologies (NASDAQ:UFPT) will be announcing earnings results tomorrow morning. Here’s what to look for. 
Via StockStory
Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be announcing earnings results tomorrow morning. Here’s what you need to know. 
Via StockStory
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow
Lab services company Charles River Laboratories (NYSE:CRL) will be reporting earnings tomorrow before the bell. Here’s what investors should know. 
Via StockStory
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For
Healthcare products company West Pharmaceutical Services (NYSE:WST) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Azenta’s (NASDAQ:AZTA) Q4 Sales Top Estimates
Life sciences company Azenta (NASDAQ:AZTA) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, but sales fell by 4.4% year on year to $147.5 million. Its non-GAAP profit of $0.05 per... 
Via StockStory
Stocks Rebound, Google Eyes Worst Drop In A Year, Gold Shatters Fresh Records: What's Driving Markets Wednesday?
Wall Street rose on Wednesday, with all major equity indices advancing as investors assessed the latest batch of corporate earnings and drew optimism from positive labor market data. 
Via Benzinga
Illumina (ILMN) Reports Earnings Tomorrow: What To Expect
Genomics company Illumina (NASDAQ:ILMN) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
IQVIA (IQV) Q4 Earnings Report Preview: What To Look For
Clinical research company IQVIA (NYSE: IQV) will be announcing earnings results tomorrow before market hours. Here’s what to look for. 
Via StockStory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.